Literature DB >> 29395989

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

David J Birnkrant1, Katharine Bushby2, Carla M Bann3, Susan D Apkon4, Angela Blackwell3, David Brumbaugh5, Laura E Case6, Paula R Clemens7, Stasia Hadjiyannakis8, Shree Pandya9, Natalie Street10, Jean Tomezsko11, Kathryn R Wagner12, Leanne M Ward8, David R Weber13.   

Abstract

Since the publication of the Duchenne muscular dystrophy (DMD) care considerations in 2010, multidisciplinary care of this severe, progressive neuromuscular disease has evolved. In conjunction with improved patient survival, a shift to more anticipatory diagnostic and therapeutic strategies has occurred, with a renewed focus on patient quality of life. In 2014, a steering committee of experts from a wide range of disciplines was established to update the 2010 DMD care considerations, with the goal of improving patient care. The new care considerations aim to address the needs of patients with prolonged survival, to provide guidance on advances in assessments and interventions, and to consider the implications of emerging genetic and molecular therapies for DMD. The committee identified 11 topics to be included in the update, eight of which were addressed in the original care considerations. The three new topics are primary care and emergency management, endocrine management, and transitions of care across the lifespan. In part 1 of this three-part update, we present care considerations for diagnosis of DMD and neuromuscular, rehabilitation, endocrine (growth, puberty, and adrenal insufficiency), and gastrointestinal (including nutrition and dysphagia) management.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29395989      PMCID: PMC5869704          DOI: 10.1016/S1474-4422(18)30024-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  115 in total

1.  Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit.

Authors:  Léonie Martigne; Julia Salleron; Michèle Mayer; Jean-Marie Cuisset; Alain Carpentier; Véronique Neve; Vincent Tiffreau; Dominique Guimber; Frédéric Gottrand
Journal:  Br J Nutr       Date:  2011-01-28       Impact factor: 3.718

Review 2.  Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis.

Authors:  Leonie H A Broersen; Alberto M Pereira; Jens Otto L Jørgensen; Olaf M Dekkers
Journal:  J Clin Endocrinol Metab       Date:  2015-04-06       Impact factor: 5.958

3.  Back pain in Duchenne muscular dystrophy: steroids are not always the culprit.

Authors:  Lee S Segal; Ryan Odgers; David Carpentieri; M Wade Shrader
Journal:  J Pediatr Orthop B       Date:  2016-01       Impact factor: 1.041

4.  Prevalence of fatigue, pain, and affective disorders in adults with duchenne muscular dystrophy and their associations with quality of life.

Authors:  Robert F Pangalila; Geertrudis A van den Bos; Bart Bartels; Michael Bergen; Henk J Stam; Marij E Roebroeck
Journal:  Arch Phys Med Rehabil       Date:  2015-02-27       Impact factor: 3.966

5.  Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Authors:  Michela Guglieri; Kate Bushby; Michael P McDermott; Kimberly A Hart; Rabi Tawil; William B Martens; Barbara E Herr; Elaine McColl; Jennifer Wilkinson; Janbernd Kirschner; Wendy M King; Michele Eagle; Mary W Brown; Tracey Willis; Deborah Hirtz; Perry B Shieh; Volker Straub; Anne-Marie Childs; Emma Ciafaloni; Russell J Butterfield; Iain Horrocks; Stefan Spinty; Kevin M Flanigan; Nancy L Kuntz; Giovanni Baranello; Helen Roper; Leslie Morrison; Jean K Mah; Adnan Y Manzur; Craig M McDonald; Ulrike Schara; Maja von der Hagen; Richard J Barohn; Craig Campbell; Basil T Darras; Richard S Finkel; Giuseppe Vita; Imelda Hughes; Tiziana Mongini; Elena Pegoraro; Matthew Wicklund; Ekkehard Wilichowski; W Bryan Burnette; James F Howard; Hugh J McMillan; Mathula Thangarajh; Robert C Griggs
Journal:  Contemp Clin Trials       Date:  2017-04-24       Impact factor: 2.226

6.  Endocrine aspects of Duchenne muscular dystrophy.

Authors:  Maria Luisa Bianchi; Doug Biggar; Kate Bushby; Alan D Rogol; Meilan M Rutter; Brian Tseng
Journal:  Neuromuscul Disord       Date:  2011-02-25       Impact factor: 4.296

7.  Why short stature is beneficial in Duchenne muscular dystrophy.

Authors:  Marko Bodor; Craig M McDonald
Journal:  Muscle Nerve       Date:  2013-07-27       Impact factor: 3.217

8.  Twenty-year follow-up of newborn screening for patients with muscular dystrophy.

Authors:  Jeffrey Chung; Andrea L Smith; Sarah C Hughes; Gabriela Niizawa; Hoda Z Abdel-Hamid; Edwin W Naylor; Timothy Hughes; Paula R Clemens
Journal:  Muscle Nerve       Date:  2015-09-10       Impact factor: 3.217

9.  Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophy.

Authors:  Molly F Wood; Sarah C Hughes; Lauren P Hache; Edwin W Naylor; Hoda Z Abdel-Hamid; M Michael Barmada; Steven F Dobrowolski; David E Stickler; Paula R Clemens
Journal:  Muscle Nerve       Date:  2014-06       Impact factor: 3.217

10.  Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy.

Authors:  Jay J Han; Evan de Bie; Alina Nicorici; Richard T Abresch; Colleen Anthonisen; Ruzena Bajcsy; Gregorij Kurillo; Craig M Mcdonald
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

View more
  212 in total

1.  High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia.

Authors:  Zoe White; Chady H Hakim; Marine Theret; N Nora Yang; Fabio Rossi; Dan Cox; Gordon A Francis; Volker Straub; Kathryn Selby; Constadina Panagiotopoulos; Dongsheng Duan; Pascal Bernatchez
Journal:  J Clin Lipidol       Date:  2020-05-29       Impact factor: 4.766

2.  Pulmonary and upper limbs function in children with early stage Duchenne muscular dystrophy compared to their healthy peers.

Authors:  Numan Bulut; Güllü Aydın; İpek Alemdaroğlu-Gürbüz; Ayşe Karaduman; Öznur Yılmaz
Journal:  Braz J Phys Ther       Date:  2020-06-05       Impact factor: 3.377

Review 3.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

4.  Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy.

Authors:  Abhinandan Batra; Ann Harrington; Donovan J Lott; Rebecca Willcocks; Claudia R Senesac; William McGehee; Dandan Xu; Sunita Mathur; Michael J Daniels; William D Rooney; Sean C Forbes; William Triplett; Jasjit K Deol; Ishu Arpan; Roxanne Bendixen; Richard Finkel; Erika Finanger; Gihan Tennekoon; Barry Byrne; Barry Russman; H Lee Sweeney; Glenn Walter; Krista Vandenborne
Journal:  Am J Phys Med Rehabil       Date:  2018-10       Impact factor: 2.159

Review 5.  Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.

Authors:  Giuseppe Vita; Gian Luca Vita; Olimpia Musumeci; Carmelo Rodolico; Sonia Messina
Journal:  Neurol Sci       Date:  2019-02-25       Impact factor: 3.307

6.  Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Authors:  Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; William J Jusko; Panteleimon D Mavroudis; Benjamin D Schwartz; Laurel J Mengle-Gaw; Edward C Smith; Jean K Mah; Michela Guglieri; Yoram Nevo; Nancy Kuntz; Craig M McDonald; Mar Tulinius; Monique M Ryan; Richard Webster; Diana Castro; Richard S Finkel; Andrea L Smith; Lauren P Morgenroth; Adrienne Arrieta; Maya Shimony; Mark Jaros; Phil Shale; John M McCall; Yetrib Hathout; Kanneboyina Nagaraju; John van den Anker; Leanne M Ward; Alexandra Ahmet; Michaelyn R Cornish; Paula R Clemens
Journal:  Pharmacol Res       Date:  2018-09-13       Impact factor: 7.658

Review 7.  Clinical management of Duchenne muscular dystrophy: the state of the art.

Authors:  Sonia Messina; Gian Luca Vita
Journal:  Neurol Sci       Date:  2018-09-14       Impact factor: 3.307

8.  Evaluating Implementation of the Updated Care Considerations for Duchenne Muscular Dystrophy.

Authors:  Katherine S Ong; Kathi Kinnett; Rieza Soelaeman; Lauren Webb; Jennifer S Bain; Ann S Martin; Christina Westfield; Julie Bolen; Natalie Street
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

9.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  David R Weber; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; Leanne M Ward
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

10.  Bone Health and Endocrine Care of Boys with Duchenne Muscular Dystrophy: Data from the MD STARnet.

Authors:  David R Weber; Shiny Thomas; Stephen W Erickson; Deborah Fox; Joyce Oleszek; Shree Pandya; Yedatore Venkatesh; Christina Westfield; Emma Ciafaloni
Journal:  J Neuromuscul Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.